Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ONDANSETRON HCL DIHYDRATE

All injection strengths: not a benefit

Other products in the same Health Canada class (A04A, A04AA) — coverage varies; not interchangeable

  • Granisetron (Kytril): limited Use 326, 454, Not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Nabilone (Cesamet): general benefit, Not a benefit
  • Aprepitant (Emend Tri-Pack): limited Use 452, 453

Auro-Ondansetron Injection · DIN 02491524 · 2mg/mL · injection solution-2mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Ondansetron Injection · DIN 02491524 Manufacturer: Auro Pharma Inc.; listing date 2022-06-30 Health Canada: Marketed since 2021-10-07 · brand AURO-ONDANSETRON INJECTION · ATC A04AA01 ONDANSETRON · form Solution · route Intravenous · ingredients ONDANSETRON (ONDANSETRON HYDROCHLORIDE DIHYDRATE) 2 MG/ML · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98138 · Verify on the e-Formulary ↗ (DIN 02491524)

Source record
DIN 02491524: Auro-Ondansetron Injection Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 562200014; group id 670; item number 1660; lccId None; manufacturer id AUR Source form: Inj Sol-2mL Pk; strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $13.2180; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02491524 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98138
Interchangeable products
Ondansetron Injection USP · DIN 02464578 · not recorded Zofran · DIN 02213745 · not recorded
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02491524
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL Some products covered without a code (check the product listing): NABILONE 56:22 Antiemetics and Antinauseants

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

NABILONE

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (4), General benefit (6) · strengths: 0.25mg, 0.5mg, 1mg · Cap

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults (18-64 years of age) Ondansetron Injection USP (ondansetron hydrochloride dihydrate) is indicated for: • the prevention of nausea and vomiting associated with emetogenic chemotherapy, including high dose cisplatin. • the prevention and treatment of postoperative nausea and vomiting. 1.1 Pediatrics Prevention of Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy (e.g. cisplatin) • Pediatrics (< 18 years): Health Canada has not authorized an indication for pediatric use. Prevention of Nausea and Vomiting Associated With Less Emetogenic Chemotherapy • Pediatrics (4-12 years of age): Intravenous ondansetron was effective and well tolerated when given to children 4-12 years of age (see 4.2 Recommended Dose and Dosage Adjustment). • Pediatrics (<4 years of age): Ondansetron Injection USP is not indicated for the treatment of children less than 4 years old. Prevention and Treatment of Post-Operative Nausea and Vomiting • Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Prevention of Nausea and Vomiting Associated with Emetogenic C… https://pdf.hres.ca/dpd_pm/00070913.PDF PM date: May 17, 2023 Source product: ONDANSETRON INJECTION USP; DIN 02464578; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Auro-Ondansetron Injection: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026